Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ktta · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Pasithea Therapeutics Corp. (KTTA) measures how much investors pay for each dollar of the company's trailing earnings. KTTA's current PE ratio of N/A is calculated by dividing its stock price of $0.58 by its TTM earnings per share of -$2.81.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Pasithea Therapeutics Corp.You KTTA | $4M | N/A | — | -$2.81 |
 AIM ImmunoTech Inc. AIM | $2M | N/A | — | -$8.62 |
 Cyclerion Therapeutics, Inc. CYCN | $13M | N/A | — | -$1.09 |
 Impact BioMedical Inc. IBO | $7M | N/A | — | -$0.38 |
 KALA BIO, Inc. KALA | $50M | N/A | — | -$3.31 |
 NovaBay Pharmaceuticals, Inc. NBY | $39M | N/A | — | -$3.80 |
 Polyrizon Ltd. PLRZ | $14M | N/A | — | -$2.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.91 | — | |
2024-12-31 FY2024 | — | $-12.69 | — | |
2023-12-31 FY2023 | — | $-12.65 | — | |
2022-12-31 FY2022 | — | $-11.04 | — | |
2021-12-31 FY2021 | — | $-1.89 | — | |
2020-12-31 FY2020 | — | $-0.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Pasithea Therapeutics Corp. (KTTA) measures how much investors pay for each dollar of the company's trailing earnings. KTTA's current PE ratio of N/A is calculated by dividing its stock price of $0.58 by its TTM earnings per share of -$2.81.
Frequently asked questions
KTTA pe ratio · 6 questionsKTTA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.58 and TTM EPS of -$2.81. Data sourced from Financial Modeling Prep via KTTA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Pasithea Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08